Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

JAMA. 1999 Nov 24;282(20):1929-33.

PMID:
10580458
2.

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.

Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ.

Curr Med Res Opin. 2004 Oct;20(10):1539-48.

PMID:
15462687
3.

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

Arch Intern Med. 2000 Oct 23;160(19):2998-3003.

PMID:
11041909
4.

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.

PMID:
12907325
5.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
6.
7.
8.

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.

Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS.

Curr Med Res Opin. 2005 May;21(5):715-22.

PMID:
15974563
10.

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.

Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E.

Arch Intern Med. 2000 Jun 26;160(12):1781-7.

PMID:
10871971
11.

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.

Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E; Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.

Aliment Pharmacol Ther. 2001 Oct;15(10):1593-601.

12.
13.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
14.

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS.

JAMA. 1999 Nov 24;282(20):1921-8.

PMID:
10580457
15.

Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.

Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA.

Pharmacoeconomics. 2001;19(10):1039-49.

PMID:
11735672
16.

Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.

Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE.

Clin Ther. 2001 Jul;23(7):1061-79. Review.

PMID:
11519771
18.

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.

Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM.

Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1101-11.

PMID:
12362101
19.

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR.

Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. Review.

20.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311

Supplemental Content

Support Center